bioAffinity Technologies, Inc. (BIAF): Entry into a Material Definitive Agreement
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 News Release bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 8, 2026) – bioAffinity Technologies, Inc .
- Instrument
- common stock
- Gross proceeds
- approximately $4 million
- Price per share
- $6.122
- Shares
- 980,072 shares
- Use of proceeds
- working capital
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The primary disclosure of new equity issuance introduces dilution risk, but the proceeds support working capital and product commercialization.
Market read
A small‑cap biotech financing event with limited market impact, primarily relevant to investors in BIAF and the biotech sector.
What to watch
The raise is tied to a specific product (CyPath® Lung) which may benefit from the additional capital if sales accelerate.
Background
bioAffinity Technologies, a Nasdaq‑listed biotech developing non‑invasive lung disease diagnostics, disclosed a $4 million equity financing via a registered direct offering and a concurrent private placement.
Ticker impact
The company filed an 8‑K announcing a $4 million registered direct financing and concurrent private placement, the first public disclosure of this capital raise.
likely modest downward pressure as investors price in dilution
Primary SEC filing reveals new equity issuance at $6.12 per share, a small raise that typically triggers short‑term sell pressure despite the cash infusion.
Market effects
Provides a modest boost to the biotech financing environment but unlikely to shift broader sector sentiment.
Limited to U.S. small‑cap biotech investors.
Minimal impact on global markets.
Counterpoint
The cash could fund near‑term growth initiatives, potentially offsetting dilution concerns if the product pipeline advances.
Key entities
- companybioAffinity Technologies, Inc.
Nasdaq‑listed biotech issuing new shares and warrants.
- entityWallachBeth Capital, LLC
Placement agent for the offering.
